Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

Trial Details

NCT ID

NCT06265350

Phase

NA

Sponsor

Sun Yat-sen University

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• Cadonilimab
• Bevacizumab
• Cryoablation

Locations (sample)

• Guanzhou, Guangdong, China|23.06828,113.37117
• Guanzhou, Guangdong, China|23.06828,113.37117

Key Eligibility Criteria

• primary or recurrent HCC;
• synchronous metastases (within one month after diagnosing of HCC) or asynchronous metastases (more than one month after diagnosis of HCC);
• pulmonary-only metastases \>5 and ≤10;
• metastases diameter ≤ 5 cm;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.